Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.68 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527065 | 0.92 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4007434 | 0.86 | CHRNB4 (0.73) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4003627 | 0.86 | CHRNB4 (0.73) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6187698 | 0.86 | CHRNB4 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4006428 | 0.84 | CHRNB2 (0.61) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5995974 | 0.81 | CHRNB4 (1.00) | CHRNB4CHRNA3 | |
| SCHEMBL2962577 | 0.81 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2959555 | 0.80 | CHRNA3 (0.67) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2961213 | 0.80 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA7 | |
| SCHEMBL2955968 | 0.78 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNB4 38/4885CHRNA3 25/4885CHRNB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.